Integrating clinical, community, and policy perspectives on human papillomavirus vaccination

Annual Review of Public Health

Volumn 31, Issue , 2010, Pages 235-252

  Fernández, Marí A E ^a   Allen, Jennifer D ^b   Mistry, Ritesh ^c   Kahn, Jessica A ^d  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Health care systems; Human papillomavirus; Policy; Psychosocial factors; Theory; Vaccine

Indexed keywords

WART VIRUS VACCINE;

CANCER SURVIVAL; CLINICAL TRIAL; DRUG COST; ENVIRONMENTAL FACTOR; HEALTH CARE POLICY; HEALTH INSURANCE; HEALTH PROGRAM; HUMAN; IMMUNIZATION; MEDICAID; MEDICARE; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; REVIEW; UTERINE CERVIX CANCER; VACCINATION; WART VIRUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CONDYLOMATA ACUMINATA; DELIVERY OF HEALTH CARE; FEMALE; HUMAN PAPILLOMAVIRUS 11; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMAN PAPILLOMAVIRUS 6; HUMANS; MALE; MIDDLE AGED; PAPILLOMAVIRUS VACCINES; PATIENT ACCEPTANCE OF HEALTH CARE; PUBLIC POLICY; UNITED STATES; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 77952717856     PISSN: 01637525     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.publhealth.012809.103609     Document Type: Review

References (117)

1. Agosti JM, Goldie SJ. 2007. Introducing HPV vaccine in developing countries\key challenges and issues. N. Engl. J. Med. 356:1908-1910
2. Ajzen I. 1991. The theory of planned behavior. Organ. Behav. Hum. Decis. Process. 50:179-211
3. Allen JD, Mohllajee AP, Shelton RC, Othus MK, Fontenot HB, Hanna R. 2009. Stage of adoption of the human papillomavirus vaccine among college women. Prev. Med. 48:420-425
4. Am Underinsurance of Adolescents: Recommendations for Improved Coverage of Preventive, Reproductive, and Behavioral Health Care Services. Pediatrics 123:191-196
5. Ault KA. 2007. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369:1861-1868
6. Ault KA. 2007. Human papillomavirus vaccines and the potential for cross-protection between related HPV types. Gynecol. Oncol. 107:S31-33
7. Averhoff F, Linton L, Peddecord KM, Edwards C, Wang W, Fishbein D. 2004. A middle school immunization law rapidly and substantially increases immunization coverage among adolescents. Am. J. Public Health 94:978-984
8. Bair RM, Mays RM, Sturm LA, Perkins SM, Juliar BE, Zimet GD. 2008. Acceptability to Latino parents of sexually transmitted infection vaccination. Ambul. Pediatr. 8:98-103
9. Bandura A. 1986. Social Foundations of Thought and Action: A Social Cognitive Theory. Englewood Cliffs, NJ: Prentice Hall
10. Barr E, Sings HL. 2008. Prophylactic HPV vaccines: new interventions for cancer control. Vaccine 26:6244-6257
11. Bartholomew LK, Parcel GS, Kok G, Gottlieb NH. 2006. Planning Health Promotion Programs: An Intervention Mapping Approach. San Francisco: Jossey-Bass
12. BasuS, Chapman GB, Galvani AP. 2008. Integrating epidemiology, psychology, and economicstoachieve HPV vaccination targets. Proc. Natl. Acad. Sci. USA 105:19018-19023
13. Bauman NM, Smith RJ. 1996. Recurrent respiratory papillomatosis. Pediatr. Clin. North Am. 43:1385-1401
14. Becker MH. 1974. The Health Belief Model and personal health behavior. Health Educ. Monogr. 2:324-508
15. Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, et al. 2006. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 118:2135-2145
16. Boehner CW, Howe SR, Bernstein DI, Rosenthal SL. 2003. Viral sexually transmitted disease vaccine acceptability among college students. Sex Transm. Dis. 30:774-778
17. Brabin L, Roberts SA, Farzaneh F, Kitchener HC. 2006. Future acceptance of adolescent human papil-lomavirus vaccination: a survey of parental attitudes. Vaccine 24:3087-3094
18. Brabin L, Roberts SA, Stretch R, Baxter D, Chambers G, et al. 2008. Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: prospective cohort study. BMJ 336:1056-1058
19. Brewer NT, Fazekas KI. 2007. Predictors of HPV vaccine acceptability: a theory-informed, systematic review. Prev. Med. 45:107-114
20. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, et al. 2009. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J. Infect. Dis. 199:926-935
21. Castellsague X, de Sanjose S, Aguado T, Louie KS, Bruni L, et al., eds. 2007. HPV and cervical cancer in the world: 2007 report. Vaccine 25(Suppl. 3):c1-230
22. Dis. Control Prev. Natl. Cent. Chron. Dis. Prev. Health Promot. 2008. Youth Risk Behavior Surveillance System: Youth Online: Comprehensive Results: United States 2007: Sexual Behaviors: Percentage of Students Who Have Ever Had Sexual Intercourse, by Grade. Http://apps. Nccd. Cdc. Gov/yrbss/
23. Chan SS, Cheung TH, Lo WK, Chung TK. 2007. Women's attitudes on human papillomavirus vaccination to their daughters. J. Adolesc. Health 41:204-207
24. Conroy K, Rosenthal SL, Zimet GD, Jin Y, Bernstein DI, et al. 2009. Human papillomavirus vaccine uptake, predictors of vaccination, and self-reported barriers to vaccination in young women eligible for catch-up vaccination. J. Womens Health. In press
25. Constantine NA, Jerman P. 2007. Acceptance of human papillomavirus vaccination among Californian parents of daughters: a representative statewide analysis. J. Adolesc. Health 40:108-115
26. Daley MF, Crane LA, Chandramouli V, Beaty BL, Barrow J, et al. 2006. Influenza among healthy young children: changes in parental attitudes and predictors of immunization during the 2003 to 2004 influenza season. Pediatrics 117:e268-77
27. Daley MF, Liddon N, Crane LA, Beaty BL, Barrow J, et al. 2006. A national survey of pediatrician knowledge and attitudes regarding human papillomavirus vaccination. Pediatrics 118:2280-2289
28. Davis K, Dickman ED, Ferris D, Dias JK. 2004. Human papillomavirus vaccine acceptability among parents of 10-to 15-year-old adolescents. J. Low Genit. Tract. Dis. 8:188-194
29. Dempsey AF, Zimet GD, Davis RL, KoutskyL. 2006
30. de Visser R, McDonnell E. 2008. Correlates of parents' reports of acceptability of human papilloma virus vaccination for their school-aged children. Sex Health 5:331-338
31. Dinh TA, Rosenthal SL, Doan ED, Trang T, Pham VH, et al. 2007. Attitudes of mothers in Da Nang, Vietnam toward a human papillomavirus vaccine. J. Adolesc. Health 40:559-563
32. Downs LS, Smith JS, Scarinci I, Flowers L, Parham G. 2008. The disparity of cervical cancer in diverse populations. Gynecol. Oncol. 109(2 Suppl.):s22-30
33. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, et al. 2007. Prevalence of HPV infection among females in the United States. JAMA 297:813-819
34. Euler GL, Lu P, Singleton JA. 2008. Vaccination coverage among U. S. adults: National Immunization Survey\Adult, 2007. http://www. cdc. gov/vaccines/stats-surv/nis/downloads/nis-adult-summer-2007. pdf
35. Fazekas KI, Brewer NT, Smith JS. 2008. HPV vaccine acceptability in a rural Southern area. J. Womens Health (Larchmt) 17:539-548
36. Fernandez ME, McCurdy S, Arvey S, Morales-Campos D, Tyson S, Useche B, Mitchell-Bennett L, Sandreson M. 2009. HPV knowledge, attitudes, and cultural beliefs among Hispanic men and women in south Texas. Ethn. Health. In press
37. Ferris DG, Waller JL, Owen A, Smith J. 2007. Midadult women's attitudes about receiving the prophylactic human papillomavirus vaccine. J. Low Genit. Tract. Dis. 11:166-172
38. Ferris DG, Waller JL, Owen A, Smith J. 2008. HPV vaccine acceptance among mid-adult women. J. Am. Board Fam. Med. 21:31-37
39. Fishbein M. 2008. A reasoned action approach to health promotion. Med. Decis. Making 28:834-844
40. Fishbein M, Ajzen I. 1975. Belief, Attitude, Intention and Behavior: An Introduction to Theory and Research. Reading, MA: Addison Wesley
41. Fishbein M, Triandis HC, Kanfer FH, Becker M, Middlestadt SE, Eichler A. 2001. Factors influencing behavior and behavior change. In Handbook of Health Psychology. ed. A Baum, TA Revenson, JE Singer, pp. 3-17. Mahwah, NJ: Erlbaum
42. Fraser C, Tomassini JE, Xi L, Golm G, WatsonM, et al. 2007. Modeling the long-term antibody response ofa human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine25:4324-4333
43. Freeman HP, Wingrove BK. 2005. Excess cervical cancer mortality: a marker for low access to health care in poor communities. Rep. NIH Publ. No. 05-5282, Natl. Cancer Inst., Cent. Reduce Cancer Health Dispar., Rockville, MD
44. Friedman AL, Shepeard H. 2007. Exploring the knowledge, attitudes, beliefs, and communication preferences of the general public regarding HPV: findings from CDC focus group research and implications for practice. Health Educ. Behav. 34:471-485
45. Fut. II Study Group. 2007. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med. 356:1915-1927
46. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, et al. 2007. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med. 356:1928-1943 (Pubitemid 46740303)
47. Gerend MA, Barley J. 2009. Human papillomavirus vaccine acceptability among young adult men. Sex Transm. Dis. 36:58-62
48. Gerend MA, Lee SC, Shepherd JE. 2007. Predictors of human papillomavirus vaccination acceptability among underserved women. Sex Transm. Dis. 34:468-471
49. Gerend MA, Magloire ZF. 2008. Awareness, knowledge, and beliefs about human papillomavirus in a racially diverse sample of young adults. J. Adolesc. Health 42:237-242
50. Gerend MA, Shepherd JE. 2007. Using message framing to promote acceptance of the human papillo-mavirus vaccine. Health Psychol. 26:745-752
51. Gerend MA, Shepherd JE, Monday KA. 2008. Behavioral frequency moderates the effects of message framing on HPV vaccine acceptability. Ann. Behav. Med. 35:221-229
52. Glasier A, Baird D. 1998. The effects of self-administering emergency contraception. N. Engl. J. Med. 339:1-4
53. Gnanasekaran SK, Finkelstein JA, HohmanK, O'Brien M, Kruskal B, Lieu T. 2006. Parental perspectives on influenza vaccination among children with asthma. Public Health Rep. 121:181-188
54. Green LW, Kreuter MW. 2005. Health Program Planning: An Educational and Ecological Approach. New York: McGraw-Hill
55. Harper D, Gall S, Naud P, Quint W, Dubin G, et al. 2008. Sustained immunogenicity and high efficacy against HPV-16/18 related cervical neoplasia: long-term follow up through 6. 4 years in women vaccinated with Cervarix. Presented at Annu. Meet. Soc. Gynecol. Oncol. (Abstr.)
56. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, et al. 2006. Sustained efficacy up to 4. 5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367:1247-1255
57. Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, et al. 2007. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 298:743-753
58. HopenhaynC, ChristianA, Christian WJ, Schoenberg NE. 2007. Human papillomavirus vaccine: knowledge and attitudes in two Appalachian Kentucky counties. Cancer Causes Control 18:627-634
59. Hughes J, Cates JR, Liddon N, Smith JS, Gottlieb SL, Brewer NT. 2009. Disparities in how parents are learning about the human papillomavirus vaccine. Cancer Epidemiol. Biomarkers Prev. 18:363-372
60. Insinga RP. 2006. Annual productivity costs due to cervical cancer mortality in the United States. Womens Health Issues 16:236-242
61. Insinga RP, Dasbach EJ, Elbasha EH. 2005. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics 23:1107-1122
62. Inst. Med. 2004. Financing Vaccines in the 21st Century: Assuring Access and Availability. Washington, DC: Natl. Acad.
63. Ishibashi KL, Koopmans J, Curlin FA, Alexander KA, Ross LF. 2008. Paediatricians' attitudes and practices towards HPV vaccination. Acta Paediatr. 97:1550-1556
64. Jacobs RJ, Meyerhoff AS. 2004. Effect of middle school entry requirements on hepatitis B vaccination coverage. J. Adolesc. Health 34:420-423
65. Jacobson VJ, Szilagyi P. 2005. Patient reminder and patient recall systems to improve immunization rates. Cochrane Database Syst. Rev. 3:CD003941
66. JenkinsD. 2008. Areviewofcross-protection against oncogenic HPVbyanHPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. Gynecol. Oncol. 110:S18-25
67. Joura EA, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, et al. 2008. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 26:6844-6851
68. Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, et al. 2007. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369:1693-1702
69. Kahn J, Ding L, Huang B, Zimet G, Rosenthal S, Frazier L. 2009. Mothers' intention for their daughters and themselves to receive the human papillomavirus vaccine: A national study of nurses. Pediatrics. 123:1430-1445
70. Kahn JA, Cooper HP, Vadaparampil S, Pence B, Weinberg A, et al. 2009. Human papillomavirus vaccine recommendations and agreement with mandated human papillomavirus vaccination for 11-to 12 year-old girls: a state-wide survey of Texas physicians. Cancer Epidemiol. Biomarkers Prev. 18:2325-2332
71. Kahn JA, Lan D, Kahn RS. 2007. Sociodemographic factors associated with high-risk human papillo-mavirus infection. Obstet. Gynecol. 110:87-95
72. Kahn JA, Rosenthal SL, Hamann T, Bernstein DI. 2003. Attitudes about human papillomavirus vaccine in young women. Int. J. STD AIDS 14:300-306
73. Kahn JA, Rosenthal SL, Jin Y, Huang B, Namakydoust A, Zimet GD. 2008. Rates of human papillo-mavirus vaccination, attitudes about vaccination, and human papillomavirus prevalence in young women. Obstet. Gynecol. 111:1103-1110
74. Kahn JA, Rosenthal SL, Tissot AM, Bernstein DI, Wetzel C, Zimet GD. 2007. Factors influencing pediatricians' intention to recommend human papillomavirus vaccines. Ambul. Pediatr. 7:367-373
75. Kahn JA, Zimet GD, Bernstein DI, Riedesel JM, Lan D, et al. 2005. Pediatricians' intention to administer human papillomavirus vaccine: the role of practice characteristics, knowledge, and attitudes. J. Adolesc. Health 37:502-510
76. Klug SJ, Hukelmann M, Blettner M. 2008. Knowledge about infection with human papillomavirus: a systematic review. Prev. Med. 46:87-98
77. Koulova A, Tsui J, Irwin K, Van DP, Biellik R, Aguado MT. 2008. Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008. Vaccine 26:6529-6541
78. Lazcano-Ponce E, Rivera L, Arillo-Santillan E, Salmeron J, Hernandez-Avila M, Munoz N. 2001. Acceptability of a human papillomavirus (HPV) trial vaccine among mothers of adolescents in Cuernavaca, Mexico. Arch. Med. Res. 32:243-247
79. Leader AE, Weiner JL, Kelly BJ, Hornik RC, Cappella JN. 2009. Effects of information framing on human papillomavirus vaccination. J. Womens Health (Larchmt) 18:225-233
80. Lenselink CH, Gerrits MM, Melchers WJ, Massuger LF, van Hamont D, Bekkers RL. 2008. Parental acceptance of human papillomavirus vaccines. Eur. J. Obstet. Gynecol. Reprod. Bio. 137:103-107
81. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. 2007. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 56:1-24
82. Marlow LA, Waller J, Wardle J. 2007. Parental attitudes to pre-pubertal HPV vaccination. Vaccine 25:1945-1952
83. Marmot M. 2000. Social determinants of health: from observation to policy. Med. J. Aust. 172:379-382
84. Marshall H, Ryan P, Roberton D, Baghurst P. 2007. A cross-sectional survey to assess community attitudes to introduction of human papillomavirus vaccine. Aust. N. Z. J. Public Health 31:235-242
85. Mays RM, Zimet GD. 2004. Recommending STI vaccination to parents of adolescents: the attitudes of nurse practitioners. Sex Transm. Dis. 31:428-432
86. McCracken M, Olsen M, Chen MS Jr, Jermal A, Thun M, et al. 2007. Cancer incidence, mortality, and associated risk factors among Asian-Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. CA Cancer J. Clin. 57(4):190-205
87. Natl. Found. Infect. Dis. 2008. Call to action: Adolescent vaccination\bridging from a strong foundation to a healthy adulthood. http://www. nfid. org/pdf/publications/adolescentvacc. pdf
88. Ogilvie GS, Remple VP, Marra F, McNeil SA, Naus M, et al. 2007. Parental intention to have daughters receive the human papillomavirus vaccine. CMAJ 177:1506-1512
89. Olshen E, Mahon BE, Wang S, Woods ER. 2007. The impact of state policies on vaccine coverage by age 13 in an insured population. J. Adolesc. Health 40:405-411
90. Oster NV, Phillips-Tangum CA, Averhoff F, Howell K. 2005. Barriers to adolescent immunization: a survey of family physicians and pediatricians. J. Am. Board Fam. Pract. 18:13-19
91. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, et al. 2007. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369:2161-2170
92. Raley JC, Followwill KA, Zimet GD, Ault KA. 2004. Gynecologists' attitudes regarding human papilloma virus vaccination: a survey of Fellows of the American College of Obstetricians and Gynecologists. Infect. Dis. Obstet. Gynecol. 12:127-133
93. Reisinger KS, Block SL, Lazcano-Ponce E, Samakoses R, Esser MT, et al. 2007. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr. Infect. Dis. J. 26:201-209
94. Riedesel JM, Rosenthal SL, Zimet GD, Bernstein DI, Huang B, et al. 2005. Attitudes about human papillomavirus vaccine among family physicians. J. Pediatr. Adolesc. Gynecol. 18:391-398
95. Ries LAG, Melbert D, Krapcho M, Mariotto A, Miller BA, et al., eds. 2007. SEER cancer statistics review, 1975-2004. Natl. Cancer Inst. http://seer. cancer. gov/csr/1975 2004/
96. Rosenthal SL, Rupp R, Zimet GD, Meza HM, Loza ML, et al. 2008. Uptake of HPV vaccine: demographics, sexual history and values, parenting style, and vaccine attitudes. J. Adolesc. Health 43:239-245
97. Samoff E, Dunn A, VanDevanter N, Blank S, Weisfuse IB. 2004. Predictors of acceptance of hepatitis B vaccination in an urban sexually transmitted diseases clinic. Sex Transm. Dis. 31:415-420
98. Sauvageau C, Duval B, Gilca V, Lavoie F, Ouakki M. 2007. Human papilloma virus vaccine and cervical cancer screening acceptability among adults in Quebec, Canada. BMC Public Health 7:304
99. Schaffer SJ, Humiston SG, Shone LP, Averhoff FM, Szilagyi PG. 2001. Adolescent immunization practices: a national survey of US physicians. Arch. Pediatr. Adolesc. Med. 155:566-571
100. Schwarz EB, Jackson R, Darney PD, Freedman L. 2002. Advance provision of emergency contraception: a randomized controlled trial. J. Gen. Intern. Med. 17:250 (Abstr.)
101. Shefer A, Markowitz L, Deeks S, Tam T, Irwin K, et al. 2008. Early experience with human papillomavirus vaccine introduction in the United States, Canada and Australia. Vaccine 26(Suppl. 10):K68-75
102. Slomovitz BM, Sun CC, Frumovitz M, Soliman PT, Schmeler KM, et al. 2006. Are women ready for the HPV vaccine? Gynecol. Oncol. 103:151-154
103. Sperber NR, Brewer NT, Smith JS. 2008. Influence ofparent characteristics and disease outcome framing on HPV vaccine acceptability among rural, Southern women. Cancer Causes Control 19:115-118
104. StretchR, Roberts SA, McCann R, Baxter D, Chambers G, et al. 2008. Parental attitudes and information needs in an adolescent HPV vaccination programme. Br. J. Cancer 99:1908-1911
105. Szilagyi PG, Bordley C, Vann JC, Chelminski A, Kraus RM, et al. 2000. Effect of patient reminder/recall interventions on immunization rates: a review. JAMA 284:1820-1827
106. Szilagyi PG, Shone LP, Barth R, Kouides RW, Long C, et al. 2005. Physician practices and attitudes regarding adult immunizations. Prev. Med. 40:152-161
107. Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, et al. 2006. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br. J. Cancer 95:1459-1466
108. Viswanath K, Breen N, Meissner H, Moser RP, Hesse B, et al. 2006. Cancer knowledge and disparities in the information age. J. Health Commun. 11(Suppl. 1):1-17
109. Weinstock H, Berman S, Cates W Jr. 2004. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect. Sex Reprod. Health 36:6-10
110. Wilson TR, Fishbein DB, Ellis PA, Edlavitch SA. 2005. The impact of a school entry law on adolescent immunization rates. J. Adolesc. Health 37:511-516
111. Winer RL, Feng Q, Hughes JP, O'Reilly S, Kiviat NB, Koutsky LA. 2008. Risk of female human papillomavirus acquisition associated with first male sex partner. J. Infect. Dis. 197:279-282
112. Wong LP. 2008. Young multiethnic women's attitudes toward the HPV vaccine and HPV vaccination. Int. J. Gynaecol. Obstet. 103:131-135
113. WoodhallSC, LehtinenM, VerhoT, HuhtalaH, HokkanenM, KosunenE. 2007. Anticipatedacceptance of HPV vaccination at the baseline of implementation: a survey of parental and adolescent knowledge and attitudes in Finland. J. Adolesc. Health 40:466-469
114. World Health Organ. 2006. Preparing for the Introduction of HPV Vaccines: Policy and Programme Guidance for Countries. Geneva, Switz.: WHO Press
115. Zimet GD, Mays RM, Sturm LA, Ravert AA, Perkins SM, Juliar BE. 2005. Parental attitudes about sexually transmitted infection vaccination for their adolescent children. Arch. Pediatr. Adolesc. Med. 159:132-137
116. Zimet GD, Mays RM, Winston Y, Kee R, Dickes J, Su L. 2000. Acceptability of human papillomavirus immunization. J. Womens Health Gend. Based Med. 9:47-50
117. Zimet GD, Perkins SM, Sturm LA, Bair RM, Juliar BE, Mays RM. 2005. Predictors of STI vaccine acceptability among parents and their adolescent children. J. Adolesc. Health 37:179-186